|
|
||||||||
J Thorac Cardiovasc Surg 1996;112:1661-1663
© 1996 Mosby, Inc.
CARDIOPULMONARY BYPASS, |
From the University of California at Los Angeles School of Medicine, Los Angeles, Calif.
Requested for publication June 24, 1996; received for publication July 25, 1996 Accepted for publication August 2, 1996. Address for reprints: Gerald D. Buckberg, MD, Department of Cardiothoracic Surgery, UCLA Medical Center, Rm. B2-375 CHS, 10833 Le Conte Ave., Los Angeles, CA 90095-1741.
The manuscript by Reed and colleagues about the effect of glutamate and aspartate on myocardial substrate oxidation in isolated rat hearts was carried out with great biochemical expertise. The data after 30 minutes of perfusion show complete recovery of function in all perfused hearts, whether beating or arrested, with and without uptake of glutamate and aspartate. In a crystalloid preparation, there was negligible uptake of glutamate and aspartate. They observed that aspartate enters the Krebs pathway via acetyl coenzyme A; yet the standard deviation inTable III of unlabeled sources is 19 ± 18 and may not account for this offset directly.
The isolated rat heart was exposed to continuous oxygenated crystalloid perfusion for 30 minutes. This lowered control oxygen consumption rate from 53 ± 10 to 22 and 17 µmol/gm dry weight. This 60% fall in small hearts is substantially lower than that in working and arrested larger dog and pig hearts, in which oxygen uptake is reduced 90%. More important, the smaller heart took up as much oxygen with potassium as with potassium plus glutamate cardioplegia, which indicates that the 95% perfusate oxygen provided sufficient nutrition to avoid ischemia when glutamate and aspartate were used and functioned well in all preparations. I presumed that no unhealthy hearts during the stabilization period were discarded for reasons cited below.
Most prior studies show that glutamate/aspartateenriched cardioplegic solution improves function in metabolism only in injured hearts. Studies of intermittent oxygenated crystalloid solution in isolated rat hearts show that uptake of glucose and branch chain acids enhanced myocardial function,
1 delayed postischemic contracture, raised adenosine triphosphate and creatinine phosphate levels, reduced lactate dehydrogenase release after reperfusion, and confirmed this in phosphorus 31nuclear magnetic resonance studies.
2 Specific amino acid effects could not be defined. The blockade of transamination by amino oxyacetate avoids the benefits of amino acids during intermittent ischemia,
3 and my colleagues and I
4 have confirmed this after hypoxia in infant dog hearts with the use of a blood cardioplegic solution.
Pisarenko and coworkers,
5 in isolated intermittently perfused rat hearts, showed that glutamate cardioplegia lessens ammonium accumulation, increases lactate utilization, and improves high-energy phosphates. Similar findings after precardioplegic ischemia were found by Kimose and associates,
6 including the marked loss of glutamate in the reperfusate in blood-perfused hearts (to be considered subsequently). We showed augmented glutamate-aspartate uptake after brain death in dogs
7 and in hypoxic infant hearts,
8 with no changes after blood cardioplegia without preceding ischemia. Rau and coworkers
9 observed that glutamate, aspartate, arginine, and orthinine, all of which are associated with the malate-aspartate shuttle, improved posthypoxic function in rabbit hearts. This may be the primary way to transfer equivalents across the mitochondrial membrane and regulate NAD/NADH (nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide reduced form) balance. Choong and Gavin
10 evaluated hypothermic St. Thomas' Hospital cardioplegic solution with l-aspartate. Storage with this solution allowed full recovery of left ventricular function and reduced sodium and calcium uptake and high-energy phosphate decline after 10 hours. The effects were extended to 20 hours with low perfusion pressure. These electrolyte effects may be important. Lazar and associates
11 showed that adding glutamate to the storage solutions provided better results than oxygen-derived free radical scavengers (superoxide dismutase and catalase) after 5 hours
2 storage of rabbit hearts. Engelman and colleagues
12 studied regional ischemia lasting 60 minutes and showed that adding glutamate and aspartate to the cardioplegic solution produced better contractile function in the ischemic segment than in controls. We have shown this experimentally and clinically, but other electrolyte cardioplegic effects, especially hypocalcemia, may have contributed to the results.
The major finding is the relative absence of citric acid effects on oxygenated perfused rat hearts with low energy requirements. Our studies confirm this with intermittent blood cardioplegia with and without amino acids. There was no change in oxygen uptake, left ventricular compliance, or contractility after 3 to 4 hours of ischemia.
13-15 We also used only cold glutamate, and we suspect that it acted postischemically to replace Krebs cycle intermediates lost during ischemia.
14 Our use is only during warm induction and reperfusion (5 minutes each). Rosenkranz and colleagues
15 needed to study ischemia plus 5 minutes of reperfusion to confirm that glutamate and aspartate enrichment improved initial oxygen uptake, lessened anaerobic metabolism, and restored left ventricular function nearly completely. The major change of ischemia is defined under the area of study limitations, because many urgent operations are done in patients with ischemic and reperfusion damage.
Pisarenko, Lepilin, and Ivanov
16 demonstrated in patients receiving high-dose dopamine that glutamate changed lactate production to consumption, reduced ammonia, showed a fivefold increase in glutamate uptake, and improved cardiac function by intravenous infusion of glutamate without changing oxygen demands. No control studies with volume infusion were made. Similar data by Thomassen and colleagues
17 showed that intravenous glutamate reduced ischemic threshhold by pacing by decreasing ST-segment depression, lowering lactate release, reducing fatty acid content by 20%, and raising myocardial glutamate uptake by 25%. Svedjeholm and associates,
18-20 following up patients who had coronary bypass, showed glutamate release during reperfusion. They demonstrated that intravenous glutamate with glucose-insulin-potassium increased myocardial oxygen uptake of glutamate and lactate and improved cardiac performance. The change to lactate production was presumed to be due to improvement in oxygen metabolism by glutamate. This group showed also evaluated the use of glutamate and glucose-insulin-potassium in patients with coronary disease who have depressed cardiac function. They showed that adding these components after reperfusion but during bypass allows recovery and frequently avoids inotropic intervention by improving postoperative cardiac output metabolically.
21
Clearly, crystalloid cardioplegic solutions are more simple and economical to use than blood solutions. They relate to specific species. Alternatively, there are no blood components (protein, erythrocytes, leukocytes, platelets), and concentrations of ions like calcium and magnesium are different from those in blood cardioplegic solutions. They also must have higher oxygen tensions, which may be detrimental. Qui and Hearse
22 stated that blood perfusion should be used more frequently. For example, as stated in this study, insulin promotes uptake of amino acids by the heart and skeletal muscle in vitro.
23,24 Aoki
25 demonstrated that uptake of glutamate by insulin occurs only in the whole blood analyses and allowed direct passage to extracellular fluids.
It is possible that the literature cited related to substrate and ischemic hearts and differences in cardioplegic solution used, together with the acetyl coenzyme A, analyses may be different from the experimental and clinical effects of amino acid supplementation shown by others. The carbon 13nuclear magnetic resonance spectroscopy is superb. It is important to repeat these studies in an in vivo blood-perfused ischemic preparation before concluding that the amino acid benefits seen by several groups are not related to augmentation of the citric acid cycle, predominantly after reperfusion, when the heart resumes aerobic work to maintain cardiac output.
Footnotes
J THORAC CARDIOVASC SURG 1996;112:1661-3 ![]()
References
This article has been cited by other articles:
![]() |
D. Pereda, M. Castella, J.-L. Pomar, R. Cartana, M. Josa, C. Barriuso, J. Roman, and J. Mulet Elective cardiac surgery using Celsior or St. Thomas No. 2 solution: a prospective, single-center, randomized pilot study Eur. J. Cardiothorac. Surg., September 1, 2007; 32(3): 501 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. King, H. Lin, J. D. McGivan, and M.-S. Suleiman Aspartate transporter expression and activity in hypertrophic rat heart and ischaemia-reperfusion injury J. Physiol., May 1, 2004; 556(3): 849 - 858. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |